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SUMOylation and ubiquitination are two essential post translational modiﬁcations (PTMs) involved in
the regulation of important biological processes in eukaryotic cells. Identiﬁcation of ubiquitin (Ub) and
small ubiquitin-related modiﬁer (SUMO)-conjugated lysine residues in proteins is critical for under-
standing the role of ubiquitination and SUMOylation, but remains experimentally challenging. We have
developed a powerful in vitro Ub/SUMO assay using a novel high density peptide array incorporated
within a microﬂuidic device that allows rapid identiﬁcation of ubiquitination and SUMOylation sites on
target proteins. We performed the assay with a panel of human proteins and a microbial effector with
known target sites for Ub or SUMO modiﬁcations, and determined that 80% of these proteins were
modiﬁed by Ub or speciﬁc SUMO isoforms at the sites previously determined using conventional
methods. Our results conﬁrm the speciﬁcity for both SUMO isoform and individual target proteins at the
peptide level. In summary, this microﬂuidic high density peptide array approach is a rapid screening
assay to determine sites of Ub and SUMO modiﬁcation of target substrates, which will provide new
insights into the composition, selectivity and speciﬁcity of these PTM target sites.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Post translational modiﬁcations (PTMs) can dramatically affect
protein function and interactions, ultimately inﬂuencing a ple-
thora of eukaryotic cellular processes. PTMs include covalent
linkage of a small protein, such as ubiquitin (Ub), the small ubi-
quitin-like modiﬁer (SUMO), or other modiﬁcations such as
phosphoryl, acetyl and methyl groups [1,2]. Therefore, under-
standing the site and number of Ub and SUMO modiﬁcations on
target proteins may provide valuable information that can lead to
drug development or a better understanding of these PTMs with
regard to protein function and role in various host cell processes
and pathogen-host interactions [3,4]. Recent proteomic screening
approaches have identiﬁed new targets modiﬁed by Ub and SUMO,B.V. This is an open access article u
-related modiﬁer; PTM, post
y, 301 University Blvd.,
).and the number of validated substrates is rapidly increasing [5–7];
however, the number of uncharacterized proteins that are targets
of Ub/SUMO PTMs is vast.
Ub and SUMO (SUMO 1–4) are small proteins (76 and 100
amino acids, respectively) that are conjugated to substrates
through a series of enzymatic reactions [8]. Ub-activating enzyme
E1 forms a thiol-ester bond between its cysteine located in the
active site and the carboxy terminal of Ub in an ATP-dependent
manner. The ubiquitin molecule is then transferred to the second
enzyme of the complex, E2 (Ub-conjugating enzyme), before
reaching the ﬁnal enzyme, an E3 Ub protein ligase, that is essential
for binding the substrate [8]. The process can be repeated forming
chains of poly-Ub. The human genome contains4600 annotated
E3 Ub ligases, and more than 100 deubiquitinating enzymes
(DUBs) that can remove Ub from the substrate [9]. Currently, ex-
perimental identiﬁcation of Ub target sites is challenging due to
rapid turnover of ubiquitinated proteins, the relatively large size of
the Ub PTM, and an undeﬁned consensus motif.
Similar to the process of ubiquitination, SUMOylation normally
consists of three enzymatic steps: activation by enzyme E1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Overview of the peptide design and ubiquitination/SUMOylation detection
strategy. (A) All wild type peptides are 12-mers by ﬂanking a central lysine residue
with 6 N-terminal amino acids and 5 C-terminal amino acids. For each peptide, a
corresponding negative control sequence was included with alanine (A) substituted
in place of K (A control). (B) The ubiquitination/SUMOylation status of lysine (K) in
these peptides was detected using speciﬁc conjugated ﬂuorescent anti-ubiquitin or
anti-SUMO antibodies which recognize ubiquitinated or SUMOylated lysines and
produce a ﬂuorescent signal.
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(UBC9), and SUMO-ligation by an E3 ligase. Sumoylation involves
the covalent modiﬁcation of target proteins at a lysine residue
within the canonical consensus sequence JKxE/D (where J is a
large hydrophobic amino acid and x any amino acid) [10]. How-
ever, recent proteomics studies have shown that a considerable
proportion of SUMO-modiﬁed proteins do not contain consensus
sites [11]. Furthermore, a model for non-consensus SUMO target-
ing has been proposed, where SUMO-Ubc9 thioester is recruited
by a SUMO interaction motif (SIM: V/I-X-V/I-V/I), which interacts
non-covalently with SUMO located on the substrate [12]. However,
the non-consensus substrates remain largely unknown; therefore,
novel tools that allow unbiased identiﬁcation of SUMO target sites
are needed.
The identiﬁcation and validation of new Ub/SUMO substrates
and deciphering of the Ub/SUMO acceptor site in a given protein is
of considerable interest. A signiﬁcant number of known SUMOy-
lation sites in target proteins occur at the consensus motif. How-
ever, this motif also often occurs in non-SUMOylated proteins, and
many functionally important SUMO sites are known to be in
noncanonical sequences. SUMOylation sites are routinely de-
termined by mass spectrometry (MS), which has been the primary
approach for the characterization of Ub/SUMO modiﬁcations on
substrate proteomes [5–7]. However, the application of MS to
characterize Ub/SUMO sites can be hampered by low protein
quantity and purity. Puriﬁcation of intact modiﬁed species pro-
duces a peptide mixture which can be too complex for efﬁcient
detection of Ub/SUMO modiﬁed sites. Moreover, although MS is an
accurate and reproducible approach, it is not suited for rapid
analysis of lysine modiﬁcation sites. In recent years, alternative
approaches such as peptide and protein microarrays have been
developed to study phosphorylation and SUMOylation [13,14].
In this study, we developed a powerful in vitro approach to
identify sites modiﬁed by Ub/SUMO that utilizes a high density
peptide microﬂuidic chip. The approach was validated using a
panel of human proteins and one bacterial effector protein with
known Ub/SUMO sites, and the results demonstrated a high level
of concordance with traditional MS analysis for identifying Ub/
SUMO-modiﬁed sites.2. Materials and methods
2.1. Microﬂuidic peptide microarray technology for analysis of ubi-
quitination and SUMOylation
The work ﬂow for the Ub/SUMO peptide assay development
was based on previous analysis of protein–protein interaction
using a phosphopeptide microarray [15]. In this study, we detected
Ub/SUMO PTMs on unmodiﬁed peptides that were synthesized on
the chip. The various steps for this study included peptide design,
peptide chip synthesis, ubiquitination and SUMOylation reaction,
data processing and analysis. The peptides were organized into a
layout ﬁle to direct chip synthesis and data analysis using Pe-
pArray pro software (http://www.pepcyber.org/PepArray/). After
the chip synthesis, peptide based assays were conducted and the
resulting image ﬁle (consisting of all the ﬂuorescent spots of Ub/
SUMOylation) was analyzed using previously described methods
[16,17]. The various steps in peptide design, detection and the
process for identiﬁcation of Ub/SUMOylation sites of selected
proteins are provided in Figs. 1 and 2.
2.2. Source peptides
A peptide array was designed using an in-house developed
PERL program [18]. A collection of 12-mer peptides fromsequences of ubiquitinated or SUMOylated proteins conﬁrmed
experimentally by MS were selected for validation [6,7]. Peptides
(12-mer) from human and microbial target proteins (Ehrlichia)
were synthesized by ﬂanking a central lysine residue with
6 N-terminal amino acids and 5 C-terminal amino acids. For each
peptide, a corresponding negative control sequence was included
with alanine (A) substituted in place of K (A peptide). The se-
quence for all peptides used in this study, which includes the
protein name, position of lysine, SUMO isoforms and sequence are
presented in Tables 1 and 2. The designed peptides were organized
into a layout ﬁle to direct chip synthesis and data analysis. All
peptides including mutant controls with twelve residues were
synthesized directly on chips in triplicate.
2.3. Peptide chip and microﬂuidic device
The peptide chip (4k) contains 3968 pico-liter reaction cham-
bers (128 rows and 31 columns) with a single peptide synthesized
directly on the surfaces of the chamber, each reaction chamber can
generate close to 1 fmol of peptide. The microﬂuidic device
(mParaﬂos; fabricated at University of Michigan) has one inlet and
one outlet, and solution ﬂows laterally through the column
channels. The total reaction volume of the chip (1.262.0 cm2) is
10 mL and each cell can accommodate 0.2 nL of reaction volume.
Fluid is introduced to the microﬂuidic device using a micro peri-
staltic pump delivering a deﬁned volume (i.e. 50 mL/min).
2.4. Chip synthesis and post synthesis treatment
Peptide microarray synthesis was performed on the mParaﬂos
Microchip System as reported before [17,19]. Brieﬂy, a digital light
gated microarray synthesizer consisting of a DNA synthesizer
(Expedite 8909, PE Biosystems) as the automated reagent/solvent
manifold and an optical unit with the same features as described
previously [20]. The light source was a 500 W Hg lamp house
(model 66033, Oriel Instruments) with a 405 nm ﬁlter. The array
Fig. 2. Experimental outline of ubiquitination and SUMOylation assay on peptide microarray. (A) All wild type peptides are synthesized onto microﬂuidic chip using standard
t-Boc protecting amino acids and a photogenerated acid as deprotection reagent for the light-gated parallel synthesis. (B, C) The chip is blocked and incubated with
ubiquitination or SUMOylation reaction solution and cell lysate. (D) The indirect and non-speciﬁc interactors are removed by denaturing washes and PBST washes. (E) The
ubiquitination and SUMOylation status of peptides are detected using speciﬁc conjugated ﬂuorescent anti-ubiquitin or anti-SUMO antibodies. (F, G) After washing, the chip is
scanned using Anon GenePix 4400A (Molecular Devices) scanner using GenePix Pro 7 software. TIFF image ﬁles were further processed through Array-Pro Analyzer software
and pixel density values were obtained as a text ﬁle (output data) for data analysis.
Table 1
Peptides corresponding to ubiquitinated target sites.
Protein Modiﬁed K Peptide sequence (wt) Peptide sequence (ctrl)
NDUFS5 28 SGEQPYKMAGRC SGEQPYAMAGRC
NDFIP1 83 DEAERTKAEATI DEAERTAAEATI
EIF4A2 55 YAYGFEKPSAIQ YAYGFEAPSAIQ
SCAMP4 185 AGGSFQKAQTEW AGGSFQAAQTEW
DDIT4 129 LVSQVGKELLRL LVSQVGAELLRL
DIABLO 147 NHIQLVKLQVEE NHIQLVALQVEE
EIF2S2 52 PEPTEDKDLEAD PEPTEDADLEAD
UBE2N 82 YHPNVDKLGRIC YHPNVDALGRIC
Ubiquitin B-1 48 RLIFAGKQLEDG RLIFAGAQLEDG
BTF3L1P 127 LAEALPKQSVDG LAEALPAQSVDG
TRAF2 27 KTLLGTKLEAKY KTLLGTALEAKY
ADRM1 21 SRGASNKYLVEF SRGASNAYLVEF
NAT13 37 YNDKFYKDVLEV YNDKFYADVLEV
SCAMP3 313 TGASFQKAQQEF TGASFQAAQQEF
Amino acid residues in the peptides carrying a lys (K) in the ubiquitination sites are
indicated in bold letters. For each peptide, a corresponding negative control se-
quence is included with alanine (A) substituted in place of K as indicated in bold
letter. Wt (Wild-type), ctrl (control).
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peptide microarray synthesis was performed similarly to conven-
tional peptide synthesis using Boc chemistry, except that a PGA
(photo-generated acid) was formed at selected reaction sites for
N-Boc deprotection instead of TFA, allowing subsequent selective
coupling of a Boc amino acid monomer at designated sites on a
chip. After de-protection of peptides anchored on the chip, the
chip was washed with ethanol followed by 25% acetonitrile over-
night to increase the solubility of the peptide. The residual acet-
onitrile was removed by washing with PBS for 2 h at room tem-
perature. The surface blocking was conducted by incubation in
blocking solution (1% BSA, 0.5% Gelatin, 0.05% TWEEN 20 in PBS;
pH 6.8) at 4 °C, overnight. The Boc amino acids, N-hydro-
xybenzotriazole (HOBt), and 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluroniumhexaﬂuorophosphate (HBTU) were from GL
Biochem (Shanghai Ltd) marketed by LC Sciences (Houston, TX).
Other chemicals and organic solvents were ordered from Sigma-
Aldrich (St. Louis, MO). All chemicals were used without further
puriﬁcation unless otherwise stated.
Table 2
Peptides corresponding to SUMO target sites.
Protein Isoform
speciﬁcity
Modiﬁed K Peptide sequence
(wt)
Peptide sequence
(ctrl)
IkBa S1 21 GPRDGLKKERLL GPRDGLAKERLL
P53 S1 386 HKKLMFKTEGPD HKKLMFATEGPD
Elk-1 S1 249 ALPPEVKVEGPK ALPPEVAVEGPK
HDAC4 S1 559 QAGVQVKQEPIE QAGVQVAQEPIE
ANXA5 S1 29 TLRKAMKGLGTD TLRKAMAGLGTD
RANBP2 S1 1414 FALVTPKKEGHW FALVTPAKEGHW
PARP1 S1 203 KQLPGVKSEGKR KQLPGVASEGKR
HSF1 S1 298 SPLVRVKEEPPS SPLVRVAEEPPS
NCOA2 S1 258 GSEVTIKQEPVS GSEVTIAQEPVS
RPS21 S2 41 NVAEVDKVTGRF NVAEVDAVTGRF
ACIN1 S2 532 AQPLPLKIEELA AQPLPLAIEELA
HNRNPD S2 197 PDTPEEKIREYF PDTPEEAIREYF
ANAPC4 S2 772 GKPVKIKEEVLS GKPVKIAEEVLS
HNRNPC S2 229 KQAVEMKNDKSE KQAVEMANDKSE
CHD4 S2 1304 VEREIIKQEESV VEREIIAQEESV
ZMYM4 S2 273 GLLDKIKDEPDN GLLDKIADEPDN
PCNA S2 164 VVISCAKDGVKF VVISCAADGVKF
PML S1þS3 490 CPRKVIKMESEE CPRKVIAMESEE
RPS6 S3 112 LRASTSKSESSQ LRASTSASESSQ
TRIM28 S3 779 NKLTEDKADVQS NKLTEDAADVQS
UTP14A S3 733 HIINPIKAEDVG HIINPIAAEDVG
ZFP106 S3 1265 EPSQELKFSVEQ EPSQELAFSVEQ
Wiz S3 666 SPPGTVKAEEHQ SPPGTVAAEEHQ
RPS3A S3 249 GDETGAKVERAD GDETGAAVERAD
RPS11 S3 249 LLGETGKEKLPR LLGETGAEKLPR
ZBTB21 S1þS2 430 VTEVRIKTEPSS VTEVRIATEPSS
HNRNPM S1þS2 698 KGCGVVKFESPE KGCGVVAFESPE
TRIM24 S1þS2 741 FPVVIVKQESDE FPVVIVAQESDE
BEND3 S1þS2 20 LKSITVKVETEA LKSITVAVETEA
NFRKB S1þS2 488 KDQAFCKQENED KDQAFCAQENED
FOSL2 S1þS2 222 VGAVVVKQEPLE VGAVVVAQEPLE
PTRF S1þS2 161 IYQDEVKLPAKL IYQDEVALPAKL
SAFB2 S1þS2 252 SVGPDRKLAEEE SVGPDRALAEEE
SNIP1 S1þS2 30 PAGVVVKQERLS PAGVVVAQERLS
TRP120 S1þS2 432 FNPIVIKEEDKV FNPIVIAEEDKV
Amino acid residues in the peptides carrying a lys (K) in the consensus motif are
indicated in bold letters. For each peptide, a corresponding negative control se-
quence is included with alanine (A) substituted in place of K as indicated in bold
letter. Wt (Wild-type), ctrl (control).
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Human monocytic leukemia cells (THP-1) were propagated in
RPMI 1640 medium with L-glutamine and 25 mM HEPES buffer
(Invitrogen) supplemented with 1 mM sodium pyruvate (Sigma,
St. Louis, MO), 2.5 g/liter D-glucose (Sigma), and 10% fetal bovine
serum (HyClone). E. chaffeensis (Arkansas strain) was cultivated in
THP-1 cells as previously described [21]. The whole cell lysates
were extracted from E. chaffeensis-infected THP-1 cells using Ab-
cam's Whole Cell Extraction Kit (ab113475) in the presence of
20 mM N-ethylmaleimide (NEM, covalent isopeptidase inhibitor,
Sigma) and 20 mM Iodoacetamide (isopeptidase inhibitor, Sigma).
Extractions were performed according to the manufacturer’s pro-
tocol. The cell lysate protein concentrations were determined
using a protein assay (DC assay; BioRad).
2.6. Ubiquitination and SUMOylation reaction
Ubiquitination and SUMOylation reactions were performed
using a SUMOylation kit (BML-UW8955, ENZO) or ubiquitination
kit (BML-UW9920, ENZO) in presence of THP-1 cell lysates ac-
cording to the manufacturer's protocol. Three microﬂuidic chips
containing the peptide array were prepared for Ub, SUMO2/3 and
SUMO1 analysis. For SUMO1 and SUMO2/3, the array was in-
cubated with the SUMOylation Buffer, E1 enzyme, Ubc9, and
SUMO1 or SUMO2 and SUMO3, ATP, Mg2þ and freshly prepared
cell lysate. For the Ub assay, the array was incubated with E1, Ub,ATP, ubiquitinylation buffer, inorganic pyrophophatase, Mg2þ and
cell lysate. Nonspeciﬁcally bound proteins were removed by
washing with buffer containing 1% SDS, 0.1% β-mercaptoethanol
and 100 mM Tris for 30 min, followed by a PBS wash containing 1%
Tween-20 (PBST). SUMO2/3 conjugation was detected with
SUMO3 Alexa Fluor 647 antibody (Novus, 1:500). The SUMO1
signal was detected using anti-SUMO1 (1:1,000), secondary anti-
mouse IgG Alexa Fluor 594 (1:30,000) was used for ﬁnal detection.
The ubiquitin conjugation was detected by using anti-Ub Alexa
Fluor 647 antibody (Santa Cruz Biotechnology, 1:300). The detailed
procedure for SUMOylation and ubiquitination reactions is as fol-
lows: chip was washed with PBS containing 1% BSA and ﬂuid
circulated at 25 μL/min for overnight at 4 °C. The chip was washed
with PBST at 50 μL/min for 30 minutes at RT, followed by SU-
MOylation or ubiquitination reaction solution circulated at 25 μL/
min for 3 h at 37 °C. The chip was washed with 100 mM Tris
containing 1% SDS, 0.1% β-mercaptoethanol solution at 50 μL/min
for 30 min at RT, followed by PBST at 50 μL/min for 1 h at RT. Anti-
Ub Alexa Fluor 647 antibody (1:300), SUMO3 Alexa Fluor 647
antibody (1:500), or anti-SUMO1 (1:1000) in PBST was circulated
at 25 μL/min for overnight at 4 °C, then washed with PBST at
50 μL/min for 1 h at RT. For SUMO1 conjugation detection, sec-
ondary anti-mouse IgG Alexa Fluor 594 (1:30,000) was circulated
at 25 μL/min for 1 h at RT, and washed with PBST at 50 μL/min for
1 h at RT.
2.7. Chip imaging
The peptide chip was removed from the microﬂuidic device
and scanned using Anon GenePix 4400A (Molecular devices)
scanner using GenePix Pro 7 software. TIFF image ﬁles were fur-
ther processed through Array-Pro Analyzer software and pixel
density values were obtained as a text ﬁle (output data).
2.8. Statistical analysis
The pixel data was merged with the layout ﬁle using an in-
house micro-array analysis program (Excel macros) and the data
was then processed in multiple stages to obtain the ﬁnal data with
background subtracted and replicates averaged using a local re-
gression method which was used to remove system related var-
iations, such as sample amount variations, dye labeling bias, and
signal gain difference between scanners [16]. The signiﬁcant po-
sitive signals were determined by comparison with the control
peptide (A peptide) and negative controls for each assay. The data
are presented as mean7SD. Differences between wild-type and
control peptides were assessed with the two-tailed Student's t
test, and signiﬁcance was indicated by a P value ofo0.05.3. Results
3.1. Ub site validation
In previous studies, Qin's research group used MS with GST-
qUBA reagent to isolate polyubiquitinated proteins and identify
294 endogenous ubiquitination sites on 223 proteins from human
293T cells [6]. Ubiquitination sites on both abundant and scarce
regulatory proteins were identiﬁed. Although this ubiquitination
site data set contains a signiﬁcant number of substrates that are
localized to the mitochondria, implicating ubiquitination in a wide
range of mitochondrial functions, the highly conserved motif was
not deﬁned due to rapid turnover of ubiquitinated proteins and
the relatively large size of the Ub PTM. In order to further validate
these ubiquitination sites and evaluate the ability of our high
density microﬂuidic chip platform to analyze these sites in vitro, 14
Fig. 3. Signiﬁcant ubiquitination and SUMOylation signals (SUMO2/3 and SUMO1) were detected at the sites represented by peptides corresponding to lysine(K) of selected
human and microbial (Ehrlichia) target proteins (A) Representative image of a small region from the peptide chip showing ubiquitination signal of wild type NDFIP1 (NDFIP1-
W) compared with mutant control (NDFIP1-M). (B) Histogram plot of the ubiquitination signals to representing human proteins compared with mutant controls for 20
peptides containing ubiquitination sites. Data represent the means7S.D. of triplicate determinations (*, Po0.05). (C) Histogram plot of the ubiquitination signals to
representing human proteins compared with mutant controls for 28 SUMO conjugation peptides that are not ubiquitinated. Data represent the means7S.D. of triplicate
determinations (*, Po0.05). (D) Representative image of a small region from the peptide chip showing SUMO2/3 signals at K432 of TRP120 compared to the mutant control
(A432). (E, F) Histogram plot of the SUMO2/3 and SUMO1 signals for K71, K432 and K418 of TRP120 compared to the corresponding mutant controls. Data represent the
means7S.D. of triplicate determinations (*, Po0.05).
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(K) of these validated proteins were randomly selected and syn-
thesized on the chip (Table 1). A microarray on a microﬂuidic chip
containing these peptides was incubated with the E1, Ub, ATP,
Mg2þ and freshly prepared cell lysate. A diagrammatic re-
presentation of the ubiquitination assay and representative image
of a sample of NDFIP1 ubiquitination showing signal intensity
compared to the control (alanine to lysine) peptide are shown in
Fig. 3A. We analyzed fourteen peptides that were spotted on
peptide microarray which exhibited ﬂuorescent signals higher
than the mutant peptides. Eleven peptides representing around
80% of the selected proteins had ﬂuorescent signal that was sig-
niﬁcantly higher than the mutant peptides, demonstrating that the
site corresponding to known ubiquitination sites was ubiquiti-
nated in the in vitro assay (Fig. 3B). In addition, we analyzed ubi-
quitination signals for 34 SUMO conjugation peptides. Among
these peptides, SUMOylation and ubiquitination targeted the same
lysine residue in 6 peptides (RPS11, HNRNPD, PCNA, TRIM28,
HNRNPM, ANXA5). The remaining 28 peptides (negative controls)
did not contain predicted ubiquitination according to the mam-
malian Ubiquitination Site Database (mUbiSiDa) or based on ex-
perimental data [22–25]. Signiﬁcant signals for 5 peptides which
contained known ubiquitination sites were detected (Fig. 3B). Inaddition, we detected signiﬁcant signals for two peptides (NFRKB
and RNABP2) from the negative control group (Fig. 3C), suggesting
that these could be false positives. The remaining 26 peptides
were conﬁrmed as negative for PTMs in our ubiquitination assay
(Fig. 3C). In addition, the 4 peptides (ANXA5, SCAMP3, SCAMP4
and NAT13) with known Ub sites were negative when compared to
the mutant peptide.
3.2. SUMO site validation
We previously reported that the E. chaffeensis T1S effector,
TRP120, was modiﬁed by SUMO1 and SUMO2/3 isoforms in pre-
sence of E1, E2 ligase (Ubc9) at a carboxy-terminal canonical
consensus SUMO conjugation motif (K432; KEDE) in vitro and in
human cells [21]. In the present study, SUMO2/3 and SUMO1 were
detected at the site corresponding to TRP120 K432 (Fig. 3D–F),
which is consistent with our previous ﬁndings regarding TRP120
SUMOylation. Recently, Ribet’s group developed a powerful
method for identifying SUMO sites by combining SILAC-based
quantitative proteomics and immunocapture of SUMO-modiﬁed
peptides, identifying 295 SUMO1 and 167 SUMO2 sites in en-
dogenous human proteins [7], In addition, a signiﬁcant number of
SUMO3-modiﬁed Lys residues in target protein have been
Fig. 4. Signiﬁcant SUMOylation signals (SUMO2/3 and SUMO1) were detected at SUMOylation sites represented by peptides corresponding to lysine (K) of selected human
proteins. SUMO2/3 assay: (A) SUMO2 targets (B) SUMO3 targets (C) SUMO1 targets. SUMO1 assay: (D) SUMO1 targets (E) SUMO2 targets (F) SUMO3 targets. Data represent
the means7S.D. of triplicate determinations (*, Po0.05).
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useful database for which to validate our assay. In order to conﬁrm
the speciﬁcity for both SUMO isoform and individual target pro-
teins at the peptide level and evaluate our high density micro-
ﬂuidic chip platform for in vitro SUMOylation assay, peptides
(n¼34) that contained scarce and abundant SUMOylation sites
based on quantiﬁcation of SUMOylation level were synthesized
onto the chip (Table 2). Among 34 peptides, 26 contained a con-
sensus motif (JKxE/D) and 8 contained non-canonical sites.
SUMO2, SUMO3, SUMO1 and SUMO1þSUMO2/3 sites were de-
tected on 8, 7, 9, and 10 peptides, respectively. The same analysis
approach described for the ubiquitination assay was used for
SUMO1 and SUMO2/3 conjugated sites mapping. As shown in
Fig. 4A and B, of 17 SUMO2 conjugated sites selected, with a
threshold of a P value ofo0.05 indicating signiﬁcance between
each wild-type and mutant peptide for 13 SUMO2 conjugated
peptides. Of the 8 selected SUMO3 targets, 6 had ﬂuorescent sig-
nals that were signiﬁcantly higher than the mutant peptide. 14/19
proteins with conﬁrmed SUMO1 sites had signals that were sig-
niﬁcantly higher than the mutant peptide, indicating that these
peptides were indeed modiﬁed with SUMO1 (Fig. 4D). We did not
detect signiﬁcant SUMO2/3 and SUMO1 signals for 8 known SUMO
target proteins (HSF1, NCOA2, FOSL2: ZBTB21, SNIP, ACIN1, NFRKB,
and HNRNPD) when compared to the mutant peptide. Thesepeptides may represent false negatives for our SUMOylation assay.
In addition, SUMO2/3 modiﬁcations were not detected on
8 SUMO1 speciﬁc targets (Fig. 4C). Therefore, these 8 peptides are
true negatives for SUMO2/3 conjugation detection. We detected
SUMO1 signiﬁcant signal for one SUMO2 speciﬁc conjugation
peptide (RPS21), suggesting RPS21 is either a false positive, or
represents an uncharacterized SUMO1 site (Fig. 4E). The other
SUMO2/3 speciﬁc conjugation peptides (n¼14) were negative in
SUMO1 assay (Fig. 4E and F). These results demonstrate the high
isoform speciﬁcity of the in vitro SUMOylation assay corresponding
to experimentally determined SUMO2/3 and SUMO1 sites.4. Discussion
We report herein the development of an in vitro Ub/SUMO
assay with a peptide array housed within a microﬂuidic device,
and demonstrate that this assay is useful for the identiﬁcation of
different Ub/SUMO target sites. Ubiquitination and SUMOylation
are two important PTMs that play pivotal roles in in various host
cell processes [3]. Both SUMOylation and ubiquitination are re-
versible, and in some cases, dynamic cycles of conjugation/de-
conjugation may be required for regulated activity. Because of its
importance and complexity, identiﬁcation of Ub/SUMO modiﬁed
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standing of the regulatory roles of Ub and SUMO. However, it is
both time-consuming and labor-intensive to use conventional
experimental approaches to identify Ub/SUMO sites [5,28,29]. In
addition, the core consensus motif in Ub substrates is not well
deﬁned. Most SUMO substrates contain the consensus motif JKxE/
D, but 40% of SUMOylation sites are noncanonical [30].
There are two major considerations associated with detection
of Ub and SUMO targets. First, only a small fraction of target
protein is typically SUMOylated at steady state. Therefore, it is
often hard to detect by direct immunoblotting. Second, SUMOy-
lated targets are easily lost after nondenaturing lysis, due to highly
active SUMO isopeptidases. In previous years, a variety of in vitro
and in vivo approaches have been used to identify Ub/SUMO tar-
gets [5,6,7,28,29]. The most common strategy is to overexpress a
tagged version of SUMO together with a putative target protein in
cells and detect target modiﬁcation by immunoblotting with an-
tibodies speciﬁc to the tag [29]. Although this assay is limited to
transfectable material, it is still a widely used assay. Mass spec-
trometry is also an important approach for conﬁrmation of protein
SUMOylation [5–7], but this method involves protein isolation,
puriﬁcation and enrichment and requires an antibody that re-
cognizes diglycine. Moreover, it is not suitable for rapid analysis of
lysine modiﬁcation sites; however it does potentially enable
quantiﬁcation of large numbers of ubiquitination sites in a signal
proteomic experiment. It is important to emphasize that only a
small proportion of potential SUMO target proteins have been
screened by mass spectrometry through identiﬁcation of the
SUMO-GG signature peptides. Therefore, it is crucial to identify
potential SUMOylated substrates using more efﬁcient and accurate
in vitro assay in order to better understand in vivo identiﬁcation of
SUMOylation sites using overexpression system.
Compared with these conventional in vitro assay approaches, our
microﬂuidic high density peptide array approach has several ad-
vantages in ubiquitin and SUMO target detection. First, unlike re-
combinant proteins, peptides are directly probed on the chip and
enabling the large scale parallel synthesis of different peptides
without the need for expensive, inconvenient puriﬁcation step. The
beneﬁt of not using pre-synthesized peptides combined with the
spotting process is highly uniform spots. The spot density obtained
using this technology can be ten-fold higher than that of spotted chip
[31]. In addition, labeling the peptides of interest with speciﬁc dye or
radioactive material is avoided. This allows for simultaneous analysis
of up to 4000 ubiquitin or SUMO targets in one experiment. The
second advantage is a unique micro-ﬂuidic device which provides
picolitre scale reaction chambers (pico-array reactor). These types of
peptide microarrays have the additional advantage of a controlled
environment. Parameters such as time, temperature, ﬂow rate, and
ﬂow direction can be preset and controlled. In addition, the assay is
performed in a closed system (as opposed to open slides), which
minimizes ﬂuorescent antibody deterioration.
In mammals, three SUMO paralogues are commonly expressed:
SUMO1 shares about 45% identity to SUMO2 and SUMO3, while
SUMO2 and SUMO3 are 96% identical to each other [32]. The dif-
ferences between SUMO1 and SUMO2/3 are mostly found in the
second β-strand and the α-helix of both proteins [33]. In cells,
different SUMO paralogues appear to share common properties
but also have some distinct functions [34]. For example, SUMO-1
was more abundantly present on the mitotic spindle, and it was
recruited very early to the reforming nuclear envelope, and later
colocalized with chromosomes. SUMO-2 and SUMO-3 were not
found on the reassembling nuclear envelope, but accrued on
chromosomes earlier in the nuclear reformation process. There-
fore, it is important to identify and distinguish target proteins
conjugated preferentially to SUMO-1 and SUMO-2/3 in order to
better elucidate their functions. In this studies, we did not detectSUMO2/3 and SUMO1 conjugates on selected SUMO1 and SUMO2/
3 speciﬁc target peptides, respectively. This is consistent with
previous results demonstrating the preferential conjugation of
SUMO1 and SUMO2/3 by MS [7,26,27]. However, among those 11
selected peptides which contain overlapping SUMO1 and SUMO2/
3 conjugation sites, SUMO1 and SUMO2 were not detected on one
(SNIP1), and SUMO1 and SUMO2 were detected on seven others.
In addition, one SUMO1 conjugates and two SUMO2 conjugates
were speciﬁcally detected, respectively. It is known that proteins
are conjugated in vitro to SUMO-1 and SUMO-2 by the E2 enzyme
Ubc9 with similar efﬁciency [35]. This indicates that, in addition to
the SUMO isoforms, target proteins, and the E1 and E2 enzymes
that are used in SUMOylation reactions in vitro, additional factors
may be present in cells that regulate the preferential usage of
SUMO-1 or SUMO-2. E3 enzymes are likely candidates to fulﬁll this
role in vivo. In addition to differences in target protein preferences
for SUMO-1 and SUMO-2/3, the relative amount of conjugated
SUMO compared with free SUMO is also different between these
SUMO family members. It has been shown that a pools of free non-
conjugated SUMO-2/3 and SUMO1 exists in different cells [36].
Thus, cell type-speciﬁc differences in conjugation efﬁciencies of
SUMO-2/3 and SUMO1 appear to exist. Therefore, the elucidation
of the cellular mechanism underlying target protein preferences
for different SUMO family members is an important future
objective.
The human genome encodes at least two ubiquitin E1, 53 E2
and 500 E3 enzymes [6]. The appropriate pairing of E2 and E3
enzymes is an important determinant for speciﬁcity of target
ubiquitination. Considering the numerous possible combinations
of E2 and E3 enzymes, it remains challenging to identify the
speciﬁc ubiquitin E2/E3 pair required for ubiquitination of a given
substrate and to understand the molecular basis that control
speciﬁc interaction. Therefore, in our in vitro ubiquitination and
SUMOylation assays, we used cell lysates (THP-1) to provide all of
necessary E2 and E3 enzymes for E. chaffeensis TRP120 and human
protein ubiquitination site validation. In this study, we detected
ubiquitination of 16 peptides representing around 80% of the se-
lected proteins. However, we failed to detect ubiquitination on the
other four proteins (SCAMP3, SCAMP4, ANXA5 and NAT13).
Among these four proteins, SCAMP3 and SCAMP4 ubiquitination
were not conﬁrmed by SDS-PAGE gel in previous studies, and thus
those ﬁndings may represent false positives. However, we cannot
exclude that the difference observed is due to unbalanced ex-
pression level of E2 and E3 enzymes in different cells. It would be
very interesting to further study the selected ubiquitinated pro-
teins using the same human cell line used for ubiquitination site
identiﬁcation by MS. Moreover, we did not detect SUMO2 or
SUMO1 on 8 known SUMO target proteins (HSF1, NCOA2, FOSL2:
ZBTB21, SNIP, ACIN1, NFRKB, and HNRNPD) using our approach. In
addition to the cell type-speciﬁc differences in conjugation efﬁ-
ciencies of SUMO-2 and SUMO1 that may exist among these tar-
gets, these ﬁndings are most likely related to the fact that six
proteins contain phosphorylation dependent SUMO motifs (PDSM,
ΨKxExxSP, in which K is the SUMO-conjugated lysine and S the
phosphorylated serine). It is known that phosphorylation sites in
close proximity to sumoylation sites directly affect the interaction
between the substrate and the SUMO-conjugating machinery [37].
The PDSM motif was shown to signiﬁcantly increase SUMOylation
efﬁciency by mediating interactions between the target and a
basic patch on Ubc9 [38]. These six proteins contain PDSMs and
may not be phosphorylated in this in vitro sumoylation assay in
the absence of phosphatase inhibitor, therefore, it is possible that
our platform may not be suitable for sumoylation studies for those
proteins which contain PDSMs.
Ubiquitination plays a fundamental role in the pathogenesis of
many infectious diseases [4]. Recent studies have identiﬁed several
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proteasome system (UPS) during infection by pathogenic bacteria.
For example, Salmonella effectors SopE and SptP are targeted and
degraded sequentially by ubiquitination to regulate bacterial in-
vasion [4]. However, the host or bacterial E3 proteins that ubi-
quitinate these effectors are still largely unknown. In addition,
some effectors that have E3 ligase activity are highly unstable,
owing to their self-ubiquitylation activity within host cells, so they
often undergo rapid proteasome-dependent degradation. Ehrlichia
chaffeensis modulates numerous host cell processes, including
gene transcription in order to survive within the macrophage.
Using the current peptide microarray technology, we detected a
signiﬁcant SUMOylation signal at K432 in the C-terminus of
TRP120. This ﬁnding was consistent with our previous results and
reported TRP120 SUMOylated at K432 [21]. In addition, we have
identiﬁed new SUMOylation sites for other Ehrlichia chaffeensis
effector proteins with unknown sites by using this method. One of
these novel SUMOylation sites was validated by other biological
methods and was consistent with peptide array results (data not
shown). Thus, this in vitro Ub/SUMO assay can be utilized not only
to study eukaryotic protein modiﬁcations, but potentially to ana-
lyze modiﬁcations of pathogen associated proteins that exploit
eukaryotic host cell Ub/SUMO pathways.
Our data set provides insight into the SUMO consensus motif and
the functional groups of proteins being modiﬁed by SUMO under
standard growth conditions. Regardless, the conﬁrmed data set
available from validation of this approach is fairly modest compared
with the other PTMs. The MS-conﬁrmed sites were validated in over
40 proteins using our approach with a single cell line. Utilizing the
current approach to identify sites using multiple cell types and
multiple cellular treatments will undoubtedly greatly increase global
knowledge about ubiquitination and SUMOylation.5. Conclusion
We report here in the development of an in vitro Ub/SUMO mi-
croﬂuidic peptide array assay that provides robust and sensitive
method for the rapid screening of potential Ub/SUMO target sites.
The sensitivity and speciﬁcity of the assay was validated using a
panel of human proteins and a bacterial effector protein with known
ubiquitin/SUMO sites. We also demonstrate a high level of con-
cordance with traditional MS analysis for Ub/SUMO-modiﬁed sites
identiﬁcation. The results of the study revealed that this approach
can be used for rapid screening of ubiquitination and SUMOylation
sites on target proteins and conﬁrm the speciﬁcity for both SUMO
isoform and individual target proteins at the peptide level without
laborious recombinant protein expression and protein puriﬁcation.
The current results suggest that the chip-based peptide microarray
format could be useful for screening potential Ub/SUMO targets with
unknown sites, and thereby contribute to our understanding the role
of ubiquitin and SUMO enzymes within the Ubiquitin/SUMO net-
work in normal physiology as well as disease pathogenesis.Acknowledgments
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